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Abstract: Primary prevention of most folate-responsive neural tube defects (NTDs) may 
not require 400 μg folic acid/day but may be achieved by attaining a high maternal folate 
status. Using RBC folate ≥906 nmol/L as a marker for NTD risk reduction, the study aimed 
to  determine  the  change  in  blood  folate  concentrations  in  reproductive  age  women  in 
response to long-term  folic  acid supplementation  at 400 µ g/day and 140 µ g/day (dose 
designed  to  mimic  the  average  daily  folic  acid  intake  received  from  New  Zealand’s 
proposed mandatory bread fortification program). Participants were randomly assigned to a 
daily folic acid supplement of 140 µ g (n = 49), 400 µ g (n = 48) or placebo (n = 47) for 
40 weeks. RBC folate concentrations were measured at baseline, and after 6, 12, 29 and 
40 weeks.  At  40  weeks,  the  overall  prevalence  of  having  a  RBC  folate  <906  nmol/L 
decreased to 18% and 35% in the 400 µ g and 140 µ g groups, respectively, while remaining 
relatively unchanged at 58% in the placebo group. After 40 weeks, there was no evidence 
of a difference in RBC folate between the two treatment groups (P = 0.340), nor was there 
evidence  of  a  difference  in  the  odds  of  a  RBC  folate  <906  nmol/L  (P  =  0.078).  In 
conclusion, the average daily intake of folic acid received from the proposed fortification 
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program would increase RBC folate concentrations in reproductive age women to levels 
associated with a low risk of NTDs.  
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1. Introduction 
It is widely accepted that adequate maternal consumption of folic acid before pregnancy and during 
the early weeks of gestation can reduce the risk of having a child with a neural tube defect (NTD). As 
a result, public health authorities worldwide have recommended consuming 400 μg folic acid per day 
during  the  periconceptional  period  to  reduce  the  risk  of  first  occurrence  NTDs  [1–4].  This 
recommended dose is based mainly on the amount of folic acid observed to be associated with a 
reduction in NTDs in the majority of epidemiological studies [5–9]. It is also the level of intake that 
demonstrated  a  dramatic  decline  in  NTD  occurrence  in  a  large-scale,  prospective  community 
intervention  trial  in  China  [10].  Whether  an  amount  of  folic  acid  lower  than  the  current  official 
recommendation  would  be  efficacious  is  a  critical  question  yet  difficult  to  determine  by  way  of 
randomized controlled trials. Alternatively, the relation of NTD risk to maternal red blood cell (RBC) 
folate concentrations may provide insight to the influence of varying levels of folic acid intake. In a 
case-control study carried out in Ireland, Daly et al. [11] documented a dose-response relationship 
between blood folate concentrations and the incidence of NTD, reporting that the lowest category of 
NTD  risk  occurred  when  maternal  RBC  folate  concentrations  were  greater  than  906  nmol/L. 
Achieving this protective folate concentration remains a challenge among reproductive age women. 
Mandatory  folic  acid  fortification  of  enriched  cereal-grain  products  in  the  United  States  and 
Canada,  implemented  in  1998,  has  substantially  improved  the  folate  status  of  reproductive  age 
women [12]  and  resulted  in  a  significant  decline  in  NTDs  [13–20].  While  implementation  of 
fortification programs for the primary prevention of NTDs is still under debate in many countries, 
mandatory folic acid fortification of bread (140 µ g folic acid/100 g) was gazetted in New Zealand for 
September 2009 but recently deferred until May 2012 [21]. At present, there are no national data on 
the folate status of New Zealand women, nor are there complete surveillance data on the national rate 
of NTDs. Using RBC folate as a marker of NTD risk, the aim of our study was to assess the percentage 
of reproductive age women who have RBC folate concentrations above the protective level, and to 
evaluate the long-term effect of 140 μg/day (dose designed to mimic the estimated average folic acid 
intake provided by the proposed bread fortification program in New Zealand) and 400 μg/day (dose 
recommended for primary prevention of NTDs) on blood folate status. 
2. Experimental Section  
2.1. Study Participants 
A sample of healthy, reproductive age women (18–40 y) were recruited in July 2008 from the staff 
and  student  population  at  the  University  of  Otago,  Dunedin,  New  Zealand,  and  from  the  local 
community through advertisements in the newspaper and word-of-mouth. Women were not included Nutrients 2011, 3  
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in the study if they were pregnant, lactating, or were planning a pregnancy in the next 12 months. 
Additional exclusion criteria for the study were regular use of folic acid-containing supplements in the 
previous  6  months;  self-reported  history  of  cardiovascular,  gastrointestinal,  hepatic,  renal  or 
hematologic disease; and use of medications that interfere with folate metabolism (e.g., methotrexate, 
sulfasalazine, or anticonvulsants). Ethical approval was obtained from the Human Ethics Committee of 
the University of Otago, Dunedin, New Zealand, and all participants gave written, informed consent. 
This  study  was  registered  with  the  Australian  New  Zealand  Clinical  Trials  Registry  [22]  as 
ACTRN12609000215224.  
2.2. Study Protocol 
The study was a 40 week double-blinded, placebo-controlled trial conducted from August 2008 
through May 2009. Participants attended an early morning clinic at baseline, and after 6, 12, 29 and 
40 weeks.  At the baseline  visit,  sociodemographic and  general  health data  were  collected using a 
self-administered  questionnaire;  height  and  weight  were  taken  according  to  standardized 
procedures [23] and measured to the nearest 0.1 cm and 0.1 kg, respectively. At the completion of the 
baseline visit, participants were provided with electronic digital scales accurate to 1 g (Model 1017; 
Salter Housewares Ltd., Tonbridge, England) and received oral and written instructions on how to 
weigh  and  record  all  food  and  beverages  consumed  over  an  assigned  3-day  period.  Participants 
were then  randomly  assigned  through  the  use  of  non-identifying  group  codes  to  receive  either  
400 μg folic acid/day, 140 μg folic acid/day, or placebo. At each clinic visit including baseline, fasting 
blood samples (15 mL collected ≥12 h after an overnight fast) were obtained by venipuncture before 
the study tablet was administered.  
2.3. Supplements 
The study supplements were manufactured by New Zealand Nutritionals Ltd (Christchurch, New 
Zealand) as hard tablets, each containing microcrystalline cellulose as a filler (placebo), and either  
140 μg (317 nmol) folic acid, or 400 μg (907 nmol) folic acid. Folate contents of the tablets were 
analyzed by microbiological assay in our laboratory at the beginning of the study. The actual amounts 
in the tablets aimed to provide 140 μg and 400 μg folic acid were 133 μg and 359 μg folic acid, 
respectively. Participants, investigators and biostatistician were blinded to the treatment. Supplements 
were coded by a third-party and randomization data was kept strictly confidential in a sealed envelope 
until all of the data analyses had been performed. Participants were instructed to take one tablet per 
day and to return all unused pills. Three bottles of tablets were prepared for each participant, and 
distributed  at  baseline,  and  weeks  12  and  29.  Compliance  with  respect to  supplement  intake  was 
assessed by counting returned pills.  
2.4. Dietary Folate Assessment 
Dietary intake of folate was determined via 3-day weighed food records completed at baseline. The 
diet records were completed over two non-consecutive weekdays and one weekend day. The total 
folate  intakes,  in  µ g,  were  tabulated  using  an  electronic  version  of  the  2006  New  Zealand  Food Nutrients 2011, 3  
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Composition Tables [24] and expressed as an overall mean of the 3-day intake. Any unavailable foods 
in the composition table were substituted with an item of the same type with a similar folate level or, if 
available, estimated from the amount stated on the manufacturer label. In total, 128 3-day baseline diet 
records  were  entered  and  analysed.  Dietary  folate  intakes  may  have  varied  over  the  40  week 
intervention period, particular due to seasonal fluctuations in price and availability of folate-rich foods.  
2.5. Blood Sampling and Laboratory Analysis 
Blood  samples  were  collected  in  EDTA-treated  tubes,  transported  on ice  and  processed  within 
one hour of collection. After measurement of the hematocrit, red blood cell hemolysates were prepared 
(dilution (1:10) of whole blood with 1% ascorbic acid) and incubated at 37 ° C for 30 min before 
storage at −80 °C. The remaining whole blood was centrifuged (1500 g for 15 min at 4 °C) to separate 
the plasma and aliquots were stored immediately at −80 °C. Plasma and whole blood folate concentration 
was  determined  by  microbiological  assay  [25]  using  test  organism  chloramphenicol-resistant 
Lactobacillus  rhamnosus  (ATCC  27773;  American  Type  Culture  Collection,  Manassas,  VA). 
Erythrocyte folate concentration was calculated from whole-blood values using individual packed cell 
volumes and after correction for plasma folate concentration. To avoid between-run variation, all study 
visit samples from each participant were measured in one batch. Accuracy and inter-assay variability 
were monitored with the use of two external quality controls: whole blood folate standard (National 
Institute for Biological Standards and Control, Hertfordshire, United Kingdom) with a certified value 
of 29.5 nmol/L (mean 27.3 (SD 4.6); CV 17%) and a human serum folate standard reference material 
(SRM 1955, National Institute of Standards and Technology, Gaithersburg, U.S.) with a total folate 
information value as determined by microbiological assay of 44 nmol/L (mean 42.5 (SD 8.7); CV 20%). 
A plasma folate concentration <6.8 nmol/L or a RBC folate concentration <317 nmol/L was used to 
indicate folate deficiency [26].  
2.6. Statistical Analysis 
All statistical analyses were performed by using Stata (version 11, Stata Corp, College Station, TX). 
Characteristics of participants completing the study and dropping out before the final blood sample 
were compared using t-tests for continuous variables (after log-transformations where appropriate) and 
χ
2 tests for categorical variables (with Fisher’s exact test used where expected cell counts were below 5 
for more than 20% of cells). The outcome variables were plasma and RBC folate concentrations and 
suboptimal  RBC  concentration  (determined  as  <906  nmol/L).  The  following  known  or  potential 
predictors  were  identified  a  priori:  age,  BMI,  education,  ethnicity,  use  of  oral  contraceptives  and 
dietary folate. Education was collapsed into three categories: secondary school or less, post-secondary 
education (university or  college), or  advanced degree.  Participant  ethnicity was classified as New 
Zealand European, Maori and Pacific Peoples, Asian, or other ethnicities. Plasma and RBC folate 
concentrations  were  natural  log  transformed  where  this  resolved  issues  with  skew  and/or 
heteroscedasticity in residuals. Linear and logistic mixed models  were  used to assess intervention 
group effects and included a random participant effect. Difference in changes between groups was 
assessed  using  treatment  group-by-time  interactions.  Selected  error  covariance  structures 
(autoregressive, toeplitz, and unstructured) were investigated for linear mixed models to see if they Nutrients 2011, 3  
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improved model fit according to the Akaike information criterion (AIC). Non-linear associations were 
investigated, and where appropriate, modelled using fractional polynomials. Variables with P < 0.25 in 
models including treatment group, time, and their interaction were included in the final regression 
models. All tests were 2-sided with statistical significance as determined by P < 0.05. 
3. Results  
Of the 144 women enrolled in the study, 119 completed the intervention trial (Figure 1). Baseline 
characteristics of the study population by treatment group are presented in Table 1. The majority of 
participants were university educated, and identified as New Zealand European. Nearly one-third of 
the participants were classified as overweight or obese. Overall folate status of the study population 
was adequate (Table 1). Twenty-five participants were lost to the study over the 40 week intervention 
period with one participant conveying her intent to conceive and the remainder citing lack of time or 
personal reasons. No statistically significant evidence of differences were observed in treatment group, 
participant age, BMI category, ethnicity, education or baseline plasma and RBC folate concentrations 
between those participants who remained in the study and those who withdrew before the end of the 
study (all P ≥ 0.325). With respect to study supplement intake, 93% (134 out of 144) participants 
returned at least one of their three study bottles and of these, 90% (120 out of 134) had compliance  
of 70% or higher.  
Figure 1. Flow diagram of the women who participated in the randomised trial. 
 
Missing RBC folate in the 140 μg folic acid group, n = 1 at 12 and 29 weeks and n = 2 at 40 weeks; 
in the 400 μg folic acid group, n = 1 at 29 weeks; in placebo, n = 2 at 40 weeks. Nutrients 2011, 3  
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Table 1. Baseline characteristics of study population 
1. 
  All (n = 144) 
Placebo  
(n = 47) 
140 µ g folic 
acid/day (n = 49) 
400 µ g folic 
acid/day (n = 48) 
Age (y) 
2  24.5 ± 5.9  24.5 ± 5.6  24.2 ± 6.2  24.9 ± 5.8 
Weight (kg) 
2  65.5 ± 12.3  65.5 ± 12.2  66.5 ± 12.1  64.5 ± 12.7 
BMI (kg/m² ) 
2  23.7 ± 3.9  23.6 ± 3.8  24.2 ± 4.0  23.4 ± 4.0 
BMI Category, n (%)         
<18.5  7 (5)  2 (4)  2 (4)  3 (6) 
18.5–24.9  96 (67)  32 (68)  31 (63)  33 (69) 
25.0–29.9  32 (22)  10 (21)  12 (25)  10 (21) 
≥30.0  9 (6)  3 (6)  4 (8)  2 (4) 
Ethnicity, n (%) 
3         
New Zealand European  109 (76)  35 (75)  35 (71)  39 (81) 
Maori and Pacific Peoples  7 (5)  4 (9)  2 (4)  1 (2) 
Asian  17 (12)  6 (13)  8 (16)  3 (6) 
Other ethnicities  11 (8)  2 (4)  4 (8)  5 (10) 
Education, n (%) 
3         
Secondary school or less  17 (12)  3 (6)  9 (18)  5 (10) 
Post-secondary education  105 (73)  39 (83)  31 (63)  35 (73) 
Advanced degree  22 (15)  5 (11)  9 (18)  8 (17) 
Oral contraceptive use, n (%)  63 (44)  22 (47)  20 (41)  21 (44) 
Dietary Folate (µ g/day) 
4,5  255.0 ± 1.5  246.7 ± 1.5  248.0 ± 1.6  271.5 ± 1.5 
Plasma folate (nmol/L) 
4  19.9 ± 1.8  21.4 ± 1.6  19.2 ± 1.8  19.3 ± 1.9 
<6.8 nmol/L, n (%)  2 (1)  0 (0)  2 (1)  0 (0) 
Red blood cell folate (nmol/L) 
4  753.2 ± 1.6  808.5 ± 1.5  700.4 ± 1.6  756.8 ± 1.6 
<317 nmol/L, n (%)  4 (3)  1 (2)  1 (2)  2 (4) 
<906 nmol/L, n (%)  95 (66)  30 (64)  33 (67)  32 (67) 
1 There were no significant differences between the three groups;  
2 Mean ±  SD;  
3 May not be equal to 100% due to rounding;  
4 Geometric mean ±  geometric SD;  
5 Dietary folate intake from food sources only including natural folate and folic acid from fortified 
foods (due to missing data, n = 128 (n = 43 placebo, n = 43, 140 μg/day, and n = 42, 400 μg/day)). 
The  geometric  mean  plasma  and  RBC  folate  concentrations  at  baseline  and  over  the  40  week 
intervention period are shown in Table 2. Error covariance structures did not improve model fit as 
measured by AIC, and mixed models included only random effects for participants to account for 
repeated measures. For both plasma and RBC folate, statistically significant interactions between time 
and  intervention  were  observed  (both  P  <  0.001).  Relative  to  the  placebo  group,  plasma  folate 
increased  statistically  significantly  in  both  supplemented  groups;  furthermore,  the mean  (95%  CI) 
increase in plasma folate of 107% (63, 164) in the 400 μg group was statistically significantly greater 
(P = 0.007) than the group receiving 140 μg folic acid/day (50% (18, 90)). In contrast, after 40 weeks 
of supplementation, there were no statistically significant differences in the observed increases in RBC 
folate concentrations between the two treatment groups (63% (95% CI: 39, 92) versus 51% (29, 78),  
P = 0.340). Nutrients 2011, 3  
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Table 2. Plasma and red blood cell folate concentrations at baseline and over the 40 week intervention period 
1. 
Measurement and 
treatment group 
Baseline  Week 6  Week 12  Week 29  Week 40 
Difference in change from 
baseline to 40 weeks (%) 
2 
Plasma folate (nmol/L)             
Placebo 
21.1 
(17.8, 24.4) 
20.3 
(17.1, 23.5) 
19.7 
(16.6, 22.9) 
20.6 
(17.2, 24.1) 
21.0 
(17.4, 24.5) 
– 
140 μg folic acid/day 
19.5 
(16.5, 22.5) 
26.6 
(22.5, 30.8) 
28.0 
(23.6, 32.5) 
31.0 
(25.9, 36.0) 
29.0 
(24.3, 33.7) 
49.8 
(18.1, 90.1) 
3 
400 μg folic acid/day 
19.2 
(16.3, 22.2) 
37.3 
(31.2, 43.3) 
38.3 
(32.1, 44.6) 
37.3 
(31.1, 43.4) 
39.5 
(33.0, 46.1) 
107.0 
(62.7, 163.8) 
4,5 
RBC folate (nmol/L)             
Placebo 
794.4 
(696.7, 892.1) 
763.8 
(668.8, 858.8) 
707.8 
(619.2, 796.5) 
729.0 
(634.3, 823.7) 
819.0 
(711.1, 926.8) 
– 
140 μg folic acid/day 
711.8 
(626.1, 797.5) 
834.5 
(732.8, 936.1) 
849.0 
(743.4, 954.7) 
987.0 
(861.8, 1112.2) 
1111.3 
(970.3, 1252.3) 
51.4 
(29.1, 77.6) 
4 
400 μg folic acid/day 
755.5 
(664.2, 846.8) 
910.8 
(796.2, 1025.3) 
940.1 
(821.2, 1059.1) 
1121.7 
(977.9, 1265.4) 
1273.4 
(1110.2, 1436.6) 
63.4 
(39.2, 92.0) 
4 
1 Adjusted geometric means (95% CI) from models controlling for age, BMI and education (plasma folate) and education only (RBC folate). There were 
statistically significant time ×  treatment interactions for changes in plasma and RBC folate, P < 0.001 in both cases; 
2 Relative to the placebo group; 
3 Statistically significantly different change from baseline compared to placebo, P = 0.001;  
4 P < 0.001; 
5 Statistically significantly different change from baseline compared to 140 µ g folic acid/day, P = 0.007. 
 Nutrients 2011, 3  
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The decreasing prevalence of RBC folate concentration <906 nmol/L in the supplemented groups is 
illustrated  in  Figure  2.  From  baseline  to  40  weeks,  the  prevalence  of  RBC  folate  <906  nmol/L 
decreased nearly 3-fold in the 400 μg group, from 67% to 18%, and approximately 2-fold in the 
140 μg group (67% to 35%). The prevalence in the placebo group was relatively unchanged (64% to 
58%). From week 6, the  400 µ g treatment group  had  statistically  significantly  decreased odds  of 
having  a  RBC  folate  concentration  <906  nmol/L  compared  with  those  in  the  placebo  group  after 
adjusting for education and the repeated measures (P = 0.009). There was no evidence that the odds 
changed  among  women  taking  140  µ g  until  week  29  (P  <  0.001).  At  week  40,  no  statistically 
significant differences were detected in the odds ratio of having a RBC folate <906 nmol/L between 
treatment groups (P = 0.078). 
Figure 2. Unadjusted percentage of red blood cell folate concentrations <906 nmol/L (95% CI). 
 
4. Discussion and Conclusions  
The present study demonstrates that although the prevalence of folate deficiency is low, nearly 
two-thirds of our study population had baseline RBC folate concentrations below the level thought to 
be protective against NTDs (i.e., ≥906 nmol/L). Since 1996, New Zealand has permitted voluntary 
folic acid fortification of selected foods, however few foods have been fortified under this policy. It is 
estimated that the mandatory fortification of bread will increase average daily folic acid intakes among 
the target population by 136 μg. Our intervention trial was designed to evaluate changes in RBC folate 
at the proposed estimated daily intake level compared to the current official recommended dose of  
400 μg folic acid/day for the primary prevention of NTD. After 40 weeks supplementation, blood 
folate status increased significantly in both treatment groups, however there was no evidence that 
mean  RBC  folate  concentrations  were  significantly  higher  in  the  group  of  women  taking  
400  μg  folic  acid/day  as  compared  to  the  140  μg  group.  Moreover,  there  was  no  evidence  of  a 
difference in the odds of having a RBC folate <906 nmol/L between treatment groups at 40 weeks.  Nutrients 2011, 3  
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To our knowledge, this is the longest intervention trial conducted to evaluate changes in blood 
folate  indices  to  moderate  folic  acid  intake  levels.  Previous  intervention  studies  [27–29]  have 
documented that RBC folate concentrations do not appear to reach a plateau with daily folic acid 
intakes  between  100–400  μg  after  24  weeks.  Our  data  support  and  extend  these  findings,  as 
demonstrated by a continuous increase in RBC folate concentration in both folic acid treatment groups 
over the 40 week intervention period. In our study, mean RBC folate levels increased by 275 nmol/L 
among study participants receiving 140 μg folic acid/day over 29 weeks—a finding similar to that 
found by Venn et al. [27] in which RBC folate increased by 251–275 nmol/L after 24 weeks of low 
dose folate supplementation (≈100 μg folic acid/day). From 29 to 40 weeks, we observed a further 
increase in mean RBC folate concentrations of 124–151 nmol/L in both folic acid regimens. However, 
unlike the study by Venn et al. [27], we did not measure changes in plasma homocysteine. Several 
epidemiologic studies have demonstrated a positive association between homocysteine and risk of 
NTDs [30]. Venn et al. [27] reported a 9% reduction in plasma homocysteine concentrations following 
supplementation  with  100  μg  folic  acid/day  over  24-week  period.  More  recently,  a  6-month 
supplementation  study  of  200  μg  folic  acid/day  showed  that  this  intake  level  was  as  effective  as 
≥400 μg folic acid/day in lowering homocysteine concentrations in a group of healthy, older adult 
participants [31].  
Recent estimates in the United States and Canada show that folic acid fortification of the food 
supply has provided an additional intake of about 100 to 150 μg/day to reproductive age women [32,33]. 
Measurement  of  blood  folate  from  the  third  National  Health  and  Nutrition  Examination  Survey 
(NHANES  III,  1998–1994),  representing  the  period  before  fortification,  through  to  three  2-y  
post-fortification survey periods covering 1999–2004 show that RBC folate concentrations increased 
by approximately 50% in every age group after the introduction of folic acid fortification [12]. This 
increase in blood folate compares favourably to our observed increase of 51% in mean RBC folate 
concentration after ingestion of 140 μg folic acid/day over 40 weeks. Furthermore, the proportion of 
study participants in the 140 μg/day group having a RBC folate concentration ≥906 nmol/L (65%) is 
also consistent with the 60–70% of reproductive age Canadian women reported to have attained this 
optimal level of blood folate after mandatory folate fortification of the food supply [34,35].  
Folic acid fortification in countries that have implemented mandatory policies has proven to be one 
of the most successful public health interventions in reducing the prevalence rate of NTDs. In Canada, 
De Wals et al. [15] indicated that the birth prevalence of NTDs decreased from 1.58 per 1000 births 
before fortification to 0.86 per 1000 births post-fortification across seven Canadian provinces. This 
prevalence  rate  is  consistent  with  a  recent systematic  review,  which  estimated  that  approximately  
7–8 NTD cases per 10,000 births were still observed (when measuring the NTD prevalence at birth or 
from abortion) after the implementation of fortification or following periconceptional supplement use 
in  primary  prevention  studies  [36].  Moreover,  recent  data  from  the  US  National  Birth  Defects 
Prevention Study (1998–2003) reported that periconceptional use of folic acid supplements in the  
post-fortification era no longer appears to further reduce NTD risk [37] suggesting that fortification 
may  have  provided  the  necessary  level  of  folic  acid  needed  to  prevent  most  folate-responsive  
NTDs [37,38].  
The  overall  prevalence  of  NTDs  in  New  Zealand  is  difficult  to  determine  accurately  due  to 
inadequate data collection around the number of NTD-affected pregnancies. Complete data (terminations, Nutrients 2011, 3  
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stillbirths and live births) are only available for 1998 to 2003. These annual totals demonstrate a 
downward trend in the rate of NTD affected pregnancies rate from 17.4 to 11.2 per 10,000 births [39]. 
In  2003,  NTD  rates  were  the  highest  in  early  pregnancy  terminations  (5.7  cases  per  10,000  total 
births), followed by live births (3.4 per 10,000) and foetal deaths (2.1 per 10,000) [40]. An assessment 
of the potential effect of incremental increases in folic acid intake on NTDs in New Zealand was 
undertaken in 2005 by Bower et al. [41]. On the basis of this assessment, the proposed mandatory 
bread fortification program is anticipated to reduce the prevalence of NTDs by 4–14% (or up to 20%) 
per year from an estimated 70–75 NTD-affected pregnancies. This projection was calculated using the 
dose-response relationship in serum folate described by Wald et al. [42] and the proportional risk of 
NTDs to a given serum folate level from nested case-control analysis by Daly et al. [11]. It has been 
noted, however, that the model developed by Wald et al. [42] likely underestimates the rise in serum 
folate concentrations (2.3 nmol/L increase for every 100 μg intake of folic acid/day) because 4 of the 
6 studies included in the analysis were not of sufficient duration to achieve a plateau in serum folate 
concentrations  (i.e.,  ~6  weeks  needed  when  ≤200  μg  folic  acid/day  is  consumed)  [43].  Thus,  the 
projected NTD reduction attributed to the proposed bread fortification is likely to be underestimated. 
Our results support this notion as reflected by an observed rise of 8.5 nmol/L in mean plasma folate 
concentrations  at  12  weeks  among  participants  receiving  140  μg  folic  acid/day  compared  to  the 
expected rise of 3.2 nmol/L derived using the Wald model [42]. Furthermore, the change in steady 
state plasma folate concentration among our women consuming 140 μg folic acid per day is highly 
comparable to the calculated rise of 8.2 nmol/L derived from a regression model by Quinlivan and 
Gregory [44], which included data from 11 intervention studies of sufficient duration.  
Mandatory folic acid fortification of bread in New Zealand has been deferred until May 2012 due to 
public concerns regarding cost-effectiveness and the impact on consumer choice [21]. There are also a 
large range of public concerns over mandatory fortification in New Zealand and the effects it may have 
on non-target population groups. To date, there are no known safety concerns at the low-to-moderate 
level of intake resulting from fortification of the food supply with folic acid [45]. Currently, New 
Zealand recommends that women planning a pregnancy take 800 μg folic acid daily for 4 weeks prior 
to conception, and 12 weeks after to reduce the risk of NTDs [46]. Results from a small number of 
surveys  conducted  to  assess  supplement  use  among  reproductive  age  women  suggest  that  only  a 
minority of women comply with the recommendation  [47–49]. While optimal folic acid strategies 
continue  to  be  debated  worldwide,  the  findings  of  this  trial  are  important  as  they  allow  for  the 
evaluation of the impact of the proposed folic acid fortification programme on the target population. 
Using the endpoint of blood folate, our results suggest that the level of folic acid provided by the 
fortification program would increase RBC folate concentrations to a level associated with a low risk of 
NTDs. Moreover, given the greater response of plasma folate concentration to the proposed estimated 
level  of  intake,  NTD  risk  reduction,  as  currently  modeled,  is  likely  underestimated.  This  is  of 
particular  importance  in  light  of  recent  speculations  that  a  similar  increase  in  folic  acid  intake 
(provided by the U.S fortification program) may result in the prevention of most folate-related NTDs.  Nutrients 2011, 3  
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